Summarized by Masters of Longevity from PR Newswire.
An investor announcement about a startup using AI and ex vivo tumor testing to advance precision oncology and expand commercially; a concise look at the company, funding round, and market ambitions.
Key Takeaways
- NAVER D2SF invested in ImpriMed as part of a $10 million Series A2 bridge round.
- ImpriMed trains AI on more than 3.5 million data points combining ex vivo cell tests with genomic and clinical data.
- ImpriMed targets FDA clearance and CLIA certification for U.S.
